Clinical TrialApr 30, 2026, 08:33 AM
CANF Namodenoson Phase 2a Pancreatic Cancer Study Shows >30% Stable Disease
AI Summary
Can-Fite BioPharma Ltd. announced positive clinical data from its Phase 2a study of namodenoson for advanced pancreatic cancer. The study showed preliminary evidence of clinical activity, including stable disease in over 30% of evaluable patients and prolonged treatment duration, with one patient on therapy for more than 16 months. A favorable safety profile was also observed. Full efficacy analyses, including progression-free survival and overall survival, are expected in the coming months.
Key Highlights
- Stable disease observed in >30% of evaluable patients in Phase 2a study.
- One patient on namodenoson treatment for advanced pancreatic cancer extended beyond 16 months.
- 35% of patients remain on therapy and follow up in the Phase 2a study.
- Namodenoson demonstrated a favorable safety and tolerability profile, consistent with prior reports.
- The Phase 2a study enrolled 20 evaluable patients with advanced pancreatic adenocarcinoma.
- Namodenoson has received Orphan Drug Designation from the U.S. FDA for pancreatic cancer.